# 2026-13581: DEA Targets Three New Mitragynine Compounds for Schedule I

2026-13581, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2026-07-06, effective 2026-07-06; PRIA reads it as touching household money (as of 2026-07-13).

- Canonical: https://policyrisk.com/federal-register/2026-13581
- As of: 2026-07-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13581
- Title: Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 40909
- Published: 2026-07-06
- Effective: 2026-07-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-13

## In one line

DEA Targets Three New Mitragynine Compounds for Schedule I

## Summary

Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.

## Abstract

The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.

## Effects PRIA read

- Possession Becomes a Schedule I Offense: cost, high. If you possess mitragynine pseudoindoxyl, MGM-15, or MGM-16 after the temporary order is published, you will be subject to Schedule I rules and the CSA's civil and criminal penalties. The temporary order will take effect on the date it is published in the Federal Register (to be published on or aft…
- Researchers Face Schedule I Requirements: cost, high. If you conduct research, instructional activities, or chemical analysis with mitragynine pseudoindoxyl, MGM-15, or MGM-16, those activities will be subject to Schedule I regulatory controls and associated administrative requirements and sanctions once the temporary order is published. The temporary…
- Retailers and Vendors Lose Legal Market Access: cost, high. Retailers, online vendors, vape shops, gas stations, and other sellers of products containing these chemicals will be subject to Schedule I prohibitions on manufacture and distribution when the temporary order is published. Selling or distributing these substances will trigger the CSA's criminal an…
- Temporary Scheduling Period Set (2 + 1 Years): cost, medium. The temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I will remain in effect for two years from the order's publication date, with a possible one-year extension if regular scheduling proceedings are initiated. The DEA intends to publish the temporary scheduling order…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-13581 on federalregister.gov](https://www.federalregister.gov/documents/2026/07/06/2026-13581/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and)
- [2026-13581 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-07-06/pdf/2026-13581.pdf)

## Related
- [Previous: 2026-13580, Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine…](https://policyrisk.com/federal-register/2026-13580)
- [Next: 2026-13586, Registering NFA Firearms That Fall Out of Government Contract](https://policyrisk.com/federal-register/2026-13586)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13581 (as of 2026-07-13).
